Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346383 | 0.88 | POLB (0.49) | SLC6A4HTTSMPD1ALDH1A1POLB | |
| SCHEMBL1344274 | 0.86 | MAPT (0.50) | SLC6A4KMT2AKDM4EHTTL3MBTL1 | |
| SCHEMBL5050751 | 0.85 | KMT2A (0.55) | KMT2AMAOBKDM4EHTTCREBBP | |
| SCHEMBL10034777 | 0.85 | GSK3B (0.45) | SLC6A4KMT2AKDM4EHTTSMPD1 | |
| SCHEMBL10034776 | 0.84 | KMT2A (0.47) | KMT2AMAOBKDM4EHTTCREBBP | |
| SCHEMBL979369 | 0.84 | POLB (0.46) | SLC6A4KMT2AKDM4EHTTSMPD1 | |
| SCHEMBL6096092 | 0.83 | KMT2A (0.63) | KMT2AMAOBMEN1ALDH1A1HPGD | |
| SCHEMBL4775181 | 0.83 | KMT2A (0.56) | KMT2AMAOBMEN1SMPD1ALDH1A1 | |
| SCHEMBL30823363 | 0.82 | MAPT (0.46) | SLC6A4KMT2AKDM4EHTTL3MBTL1 | |
| SCHEMBL27140070 | 0.82 | MAPT (0.46) | SLC6A4KMT2AKDM4EHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040389-A2 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010111673-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | SLC6A4 4107/4885KMT2A 3912/4885MAOB 1627/4885 |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | SLC6A4 4107/4885KMT2A 3912/4885MAOB 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.